Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease
Launched by DELOS CLINICAL · Apr 26, 2017
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
We are carrying out a study in Cancer-associated-thromboembolism patients in order to decide the suitable anticoagulation time. A set of exclusion criteria is being used to determine in which patients LMWH will be withdrawn. Patients are being followed after LMWH withdrawal until 6 months. Blood samples are being taken at baseline (LMWH withdrawal), 3 weeks and 3 months after. We will look for association between several biomarkers and venous thromboembolism recurrences.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with diagnosis of cancer (any) and diagnosis of pulmonary thromboembolism (PT) or venous thromboembolism (VT) , in treatment with low molecular weight heparin (LMWH).
- • Patients treated with LMWH since cancer diagnostic.
- • Signed informed consent sheet
- Exclusion Criteria:
- • Patients with life expectancy lower than 6 months
- • Pregnancy woman
- • Patients with cerebral metastasis
About Delos Clinical
Delos Clinical is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative clinical solutions. With a focus on enhancing the efficiency and effectiveness of clinical trials, Delos Clinical leverages cutting-edge technology and a patient-centered approach to streamline study design and execution. Committed to ethical practices and regulatory compliance, the organization collaborates with a diverse range of stakeholders, including pharmaceutical companies, biotech firms, and research institutions, to bring new therapies to market. Delos Clinical aims to transform the landscape of clinical research, fostering breakthroughs that address unmet medical needs and enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Remedios Otero Candelera, MD PhD
Study Chair
Hospital Universitario Virgen del Rocío IBIS
Teresa Elias, MD PhD
Principal Investigator
Hospitales Universitarios Virgen del Rocío
Isabel Blasco, MD
Principal Investigator
Hospital Universitario Virgen Macarena
Maria Rodriguez, MD
Principal Investigator
Hospital Universitario de Valme
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials